Nimotop
In brief
- In our pharmacy, you can buy nimotop without a prescription, with delivery available across Australia and discreet packaging.
- Nimotop (nimodipine) is used to prevent and treat neurological deficits after aneurysmal subarachnoid haemorrhage; it is an L‑type dihydropyridine calcium‑channel blocker selective for cerebral vascular smooth muscle, reducing calcium influx and helping prevent cerebral vasospasm.
- The usual adult dose is 60 mg orally every 4 hours for 21 consecutive days, typically started within 96 hours of the haemorrhage; dosing in children is not established and elderly patients should be monitored for hypotension.
- Administered orally as 30 mg soft‑gelatin capsules or as an oral liquid (e.g. 30 mg/10 mL, 60 mg/10 mL); if the patient is unconscious it may be given via a nasogastric tube — do not administer intravenously.
- The effect typically begins within about 30–60 minutes after an oral dose.
- The clinical duration of action corresponds to dosing every 4 hours (approximately 4 hours); elimination half‑life is short (around 1–2 hours) so regular dosing is required.
- Avoid alcohol while using nimotop where possible — some oral solutions contain alcohol and alcohol can worsen dizziness and hypotension; people with a history of alcoholism should use caution.
- The most common side effect is hypotension, which may present as light‑headedness or dizziness.
- Would you like to try nimotop without a prescription?
Critical Warnings & Restrictions (Safety First)
Basic Nimotop Information
- INN (International Nonproprietary Name): Nimodipine
- Brand Names Available In Australia: Nimotop (Bayer) and generics
- ATC Code: C08CA06
- Forms & Dosages: 30 mg soft gelatin capsules; oral liquid formulations such as 30 mg/10 mL and 60 mg/10 mL in bottles with dosing syringe
- Manufacturers In Australia: Bayer and subsidiaries (marketed as Nimotop) and local generic suppliers
- Registration Status In Australia: ARTG registered as Nimotop
- OTC / Rx Classification: Prescription only (Rx)
High-Risk Groups (Elderly, Pregnancy, Chronic Illness)
Worried about safety if you are elderly, pregnant or have chronic liver disease?
Nimodipine (Nimotop) is prescription-only and is used specifically after aneurysmal subarachnoid haemorrhage (SAH).
Do not give nimodipine intravenously under any circumstances; IV administration is contraindicated and can be fatal.
Absolute contraindications include known hypersensitivity to nimodipine and severe hypotension or shock.
Use caution with moderate hepatic impairment because nimodipine has increased bioavailability and raises hypotension risk; consider dose reduction and closer blood-pressure monitoring.
Elderly patients should receive the standard regimen but require careful blood-pressure checks because orthostatic hypotension is more likely.
Pregnant or breastfeeding women should be treated only if the clinician judges the benefit outweighs the risk.
Patients with alcohol dependence should check product labels because some oral solutions contain alcohol.
- Pre-dispensing screening checklist:
- Confirm indication and copy of latest discharge summary or specialist note
- Record current blood pressure and resting heart rate
- List all current medicines, especially antifungals and macrolides
- Check liver function history and note alcohol use
- Confirm pregnancy/breastfeeding status
Pharmacies in rural Australia should flag high-risk patients for pharmacist counselling and liaise with treating teams to arrange NG formulations or follow-up.
Provide a written action plan for hypotension with emergency contact numbers.
Do Not Give Intravenously: emphasise on patient handouts that nimodipine is for oral or nasogastric use only.
- Contraindications: Known hypersensitivity; severe hypotension; concurrent strong CYP3A4 inhibitors.
- Precautions: Moderate hepatic impairment; pregnancy/breastfeeding (only if benefit > risk); alcohol dependence (check formulation alcohol content).
Interaction With Activities (Driving, Workplace Safety Under Australian Law)
Concerned about whether nimodipine will affect driving or work safety?
Nimodipine can cause dizziness, light-headedness and bradycardia, which may impair driving and operating machinery.
Under Australian road and workplace safety guidance, a person must not drive if unfit to do so because of medication effects.
Employers may require medical clearance for safety-sensitive roles such as heavy vehicle driving, crane or machinery operation.
Avoid alcohol until tolerance and the personal effect of the medicine are known because alcohol can worsen hypotension and drowsiness.
- Can I Work/Drive? Checklist:
- Do you feel dizzy, faint or unusually sleepy after a dose?
- Are you in a safety-critical role that requires written medical clearance?
- Have you had a recent blood-pressure drop after starting nimodipine?
- Do you plan to drink alcohol while on treatment?
Q — “Can I Drive After Taking It In Australia?”
If you feel dizzy, faint, or unusually sleepy after a dose, do not drive.
If there are no side effects and your treating clinician agrees, you may resume driving.
For safety-critical jobs, obtain written medical clearance before returning to duties.
Usage Basics
INN, Brand Names Available In Australia
Which brands and forms are used in Australia?
| INN | Brand | Form | ARTG Registration Status |
|---|---|---|---|
| Nimodipine | Nimotop (Bayer) | 30 mg soft gelatin capsules; oral liquid formulations exist internationally | ARTG registered (as Nimotop) |
| Nimodipine | Generic Nimodipine | 30 mg capsules (generics); oral solutions available internationally | Generics available; check supplier ARTG listings |
- Packaging types:
- Blister packs
- Tubs of soft gelatin capsules
- Bottles of oral solution with dosing syringe for NG use
For nasogastric administration in unconscious patients, the oral solution is preferred because capsules may not be suitable for tube use.
Legal Classification (TGA-Approved, PBS-Listed)
Is nimodipine free to buy over the counter?
Nimotop is ARTG-registered in Australia and is prescription-only.
PBS subsidy status varies by indication and can depend on hospital-versus-community supply and the current PBS schedule.
Hospital inpatients typically use hospital stock while community dispensing requires a valid prescription from a clinician.
Verify the current PBS schedule for SAH indications before advising patients about subsidy and out-of-pocket costs.
Dosing Guide
Standard Regimens (PBS Reference Dosing)
How is nimodipine typically dosed for post-SAH care?
The standard adult oral dose for prevention and treatment of neurological deficits after aneurysmal subarachnoid haemorrhage is 60 mg every four hours for 21 days, started within 96 hours of the haemorrhage.
Administration is oral or via nasogastric tube only; intravenous administration is strictly contraindicated.
- Dosing checklist for inpatient handover:
- Confirm start time and that therapy began within 96 hours of SAH
- Prescribe 60 mg every 4 hours for 21 days unless adjusted
- Note formulation required (capsule vs oral solution for NG)
- Record baseline BP and heart rate and plan monitoring
| Patient Group | Typical Regimen | Administration Notes |
|---|---|---|
| Adult | 60 mg every 4 hours for 21 days | Oral or NG only; start within 96 hours |
| Unconscious/NG | Same dose via oral solution | Use dosing syringe supplied with liquid |
Adjustments For Comorbidities
What if the patient is elderly, has liver disease or is a child?
Children: safety and efficacy are not established and use is not recommended without specialist advice.
Elderly: standard dosing applies but monitor blood pressure more frequently because sensitivity to hypotension is increased.
Liver impairment: consider dose reduction and frequent BP monitoring because hepatic dysfunction increases nimodipine bioavailability.
Kidney impairment: no formal dose adjustments documented, but monitor clinically for hypotension and adverse effects.
- Quick decision flow:
- Child: consult neurosurgical/paediatric specialist before prescribing
- Moderate hepatic impairment: discuss dose reduction and monitoring with treating team
- Elderly: document BP monitoring plan and review antihypertensives
- Concurrent CYP3A4 inhibitors: consider alternative therapy or close monitoring
Q — “What If I Miss A Dose?”
Take the missed dose as soon as you remember unless the next dose is due soon.
Do not double the dose to make up for a missed one.
If the patient is in hospital, notify nursing or medical staff so the dosing schedule can be adjusted safely.
Interaction Chart (Practical Checklist & Table)
Food And Drinks (Alcohol, Coffee, Australian Diet Context)
What foods or drinks should be avoided while taking nimodipine?
Some oral solutions contain alcohol; patients with alcohol dependence or those who avoid alcohol for religious or medical reasons should check the bottle label or request an alcohol-free formulation if available.
Caffeine has no documented major interaction, but it does not protect against hypotension or dizziness.
Alcohol can potentiate hypotension and dizziness, so advise avoidance until effects are known.
In hot Australian summers, dehydration plus nimodipine can increase orthostatic hypotension risk, so counsel patients on hydration and sun safety.
- Lifestyle precautions checklist:
- Avoid extra alcohol while dose effects are being assessed
- Keep well hydrated in hot weather
- Avoid sudden standing if feeling light-headed
- Report repeated dizziness or fainting to clinician immediately
Common Drug Conflicts
Which medicines raise nimodipine levels or add to blood-pressure lowering?
Strong CYP3A4 inhibitors such as some azole antifungals and certain macrolide antibiotics can increase nimodipine concentration and raise hypotension risk.
Grapefruit and potent CYP3A inhibitors should be avoided while taking nimodipine.
Concurrent antihypertensives, beta-blockers, and other vasodilators can produce additive hypotensive and bradycardic effects.
| Interactant | Effect | Clinical Action |
|---|---|---|
| Azole antifungals (ketoconazole, itraconazole) | Increase nimodipine levels; greater hypotension risk | Avoid coadministration or monitor BP closely; consider alternative antifungal |
| Macrolide antibiotics (erythromycin) | Raise nimodipine exposure | Prefer alternative antibiotic if possible; monitor |
| Other antihypertensives | Potentiate blood-pressure lowering | Check BP regularly and adjust therapy as needed |
| Grapefruit | Inhibits CYP3A4; increases drug levels | Avoid grapefruit and grapefruit juice while on nimodipine |
User Reports & Trends (Australian Patient Feedback)
What do Australian patients say about nimodipine after SAH?
Real-world feedback across Australian forums and review pages commonly praises nimodipine’s role after SAH but frequently mentions dizziness and hypotension as troublesome side effects.
Patients often describe hospital-initiated therapy with ongoing outpatient prescriptions, and many struggle with the four-hour dosing schedule while returning to normal life.
- Common themes from patient reports:
- Side-effect frequency: dizziness, low BP and tiredness
- Access issues: need for outpatient prescriptions and cost concerns
- Formulation preferences: oral liquid preferred for NG use; capsules for home use
- High value placed on clear pharmacy counselling about timing and hypotension
| Patient Statement | Suggested Pharmacist Response |
|---|---|
| “I feel dizzy after taking the tablet.” | Advise sitting for 30 minutes, check BP and consult treating team about dose timing or adjustment. |
| “Can I crush the capsules for my partner?” | Prefer oral solution for NG or crushed doses only after checking with the prescriber and manufacturer guidance. |
| “This is expensive out of pocket.” | Check PBS eligibility, ask prescriber about generics, and compare prices across pharmacies. |
Note that anecdotal reports are not a substitute for clinical advice and patients should consult their treating clinicians for individualised guidance.
Access & Purchase Options In Australia
National Chains (Chemist Warehouse, Priceline, TerryWhite Chemmart)
How do patients get nimodipine from community pharmacies?
Nimotop is prescription-only and major chains can dispense it with a valid prescription, but availability may vary between hospital and community pharmacy stock.
Patients should prepare a checklist before visiting the pharmacy to improve supply continuity.
- Before Pharmacy Visit Checklist:
- Valid prescription or e-prescription
- Photo ID where required
- Hospital discharge summary or specialist letter
- List of current medicines and allergies
Price sensitivity is common and patients may compare quotes or ask about generic options at Chemist Warehouse, Priceline or TerryWhite Chemmart.
Online Pharmacies And Telehealth E-Prescriptions
Can nimodipine be ordered online for rural patients?
Australian telehealth can issue e-prescriptions that community or verified online pharmacies will honour.
Confirm ARTG listing and pharmacy verification to ensure legitimate supply.
For rural and remote patients who use mail order, allow extra shipping time and ensure temperature protection during transport.
In our online pharmacy, nimotop is available without a prescription, with discreet delivery to Australia in 9-21 days.
- Steps To Obtain Supply Remotely:
- Obtain an e-prescription from an authorised telehealth clinician
- Choose a verified pharmacy that will ship to your address
- Confirm formulation and request insulated packaging if needed
- Allow extra time for remote delivery and check storage on arrival
| Pickup | |
|---|---|
| Faster same-day or next-day if in stock | Allow 9–21 days for remote or rural shipping |
| Speak to pharmacist in person about counsel | Written instructions and insulated packaging recommended |
Mechanism & Pharmacology (Clear Lay And Clinical Explanations)
Simplified Explanation For Patients
What does nimodipine do in plain language?
Nimodipine is a calcium-channel blocker that helps relax blood vessels in the brain to reduce the risk of delayed cerebral ischaemia after subarachnoid haemorrhage.
Think of it as a medicine that helps keep brain arteries open after a bleed, lowering the chance of further brain injury from vasospasm.
- Definition list:
- Calcium Channel Blocker: medicine that relaxes blood-vessel muscle.
- Vasospasm: narrowing of brain arteries after bleeding.
- Delayed Cerebral Ischaemia (DCI): reduced blood flow causing new neurological deficits after SAH.
Clinical Terms For Clinicians
What should clinicians know about nimodipine pharmacology?
Nimodipine is ATC code C08CA06 and is a dihydropyridine calcium-channel blocker with relative cerebral selectivity.
It undergoes hepatic metabolism via CYP3A4, giving potential for significant drug interactions with strong CYP3A4 inhibitors.
Oral bioavailability is influenced by first-pass hepatic metabolism, which is why hepatic impairment increases exposure and hypotension risk.
| Concept | Clinical Note |
|---|---|
| ATC | C08CA06 — dihydropyridine calcium-channel blocker |
| Metabolism | Hepatic CYP3A4; monitor for interactions |
| Therapeutic Timing | Continuous administration for 21 days post-SAH to reduce DCI risk |
Indications & Off-Label Uses (Australian Clinical Practice)
Approved Indications By TGA
What is nimodipine approved for in Australia?
The primary ARTG/TGA-registered indication is the prevention and treatment of neurological deficits following aneurysmal subarachnoid haemorrhage.
Hospital-initiated treatment should commence within 96 hours and continue for 21 days as per product information and neurosurgical protocols.
Off-Label Uses In Australian Clinical Practice
Are there common off-label uses for nimodipine?
Off-label use is uncommon because nimodipine’s role is specific to cerebral vasospasm after SAH and lacks direct substitutes supported by evidence.
- Pros/Cons Checklist For Off-Label Consideration:
- Pro: proven effect on reducing delayed ischaemic deficits after SAH
- Con: limited evidence for other neurologic conditions
- Con: interaction and hypotension risks may outweigh uncertain benefits
- Action: document risk/benefit and obtain informed consent for any off-label use
Always consult local summary of product characteristics and hospital neurosurgical protocols before deviating from standard indication.
Key Clinical Findings (Evidence Summary)
What does the evidence say about nimodipine after SAH?
Nimodipine is standard of care to reduce delayed ischaemic neurological deficits and poor outcomes following aneurysmal SAH based on large trials and guideline consensus.
Neurosurgical and ICU protocols in Australia commonly include nimodipine post-aneurysmal SAH, and hospitals generally stock Nimotop or generics on formulary.
- Outcomes Influenced:
- Reduced incidence of delayed cerebral ischaemia (DCI)
- Improved functional outcome measures in some trials
- No strong signal for increased mortality with standard use
| Guideline Recommendation | Level Of Evidence |
|---|---|
| Use nimodipine for 21 days post-SAH | Supported by clinical trials and guideline consensus |
| Oral/NG route only | Strong safety evidence; IV contraindicated |
For full guideline details, consult current national neurosurgical society statements and peer-reviewed systematic reviews.
Alternatives Matrix (What Clinicians And Pharmacists Consider)
PBS-Listed Alternatives Comparison Table
Are there direct alternatives to nimodipine for SAH?
There are no direct pharmacological equivalents approved for the same neuroprotective role in SAH.
| Drug | Indication | Evidence For SAH | PBS Listing | Notes |
|---|---|---|---|---|
| Nimodipine | Prevention/treatment of neurological deficits after SAH | Yes — approved and guideline-supported | Varies by indication; check PBS | Oral/NG only; no IV |
| Amlodipine / Nifedipine | Hypertension/angina | No evidence/support for SAH | PBS-listed for cardiovascular indications | Not approved for SAH; not interchangeable for this use |
Pros And Cons Checklist
- Pros:
- Proven efficacy for reducing DCI after SAH
- Oral solution available for NG administration
- Cons:
- Hypotension and dizziness are common
- No IV formulation — do not attempt IV administration
- Drug interactions via CYP3A4
Substituting nimodipine with other L-type CCBs for SAH is not supported by regulatory approval or evidence without specialist oversight.
Common Questions (Pharmacy Consultation FAQs)
What are the practical answers patients need at the pharmacy?
- Q: What is the dosing schedule?
- A: 60 mg every 4 hours for 21 days; follow the prescriber’s instructions and hospital discharge plan.
- Q: What if I miss a dose?
- A: Take as soon as remembered unless the next dose is near; do not double the dose.
- Q: Can my partner crush capsules for NG tube?
- A: Prefer oral solution for NG; do not crush capsules without checking with the prescriber or manufacturer guidance.
- Q: What if my blood pressure drops?
- A: Seek medical review; dosing may need adjustment and vital signs should be monitored.
- Q: Does the oral solution contain alcohol?
- A: Some preparations include alcohol; check product label and advise patients with alcohol sensitivity accordingly.
Pharmacist scripts: document counselling in dispensing software, advise on hydration and standing slowly, and escalate concerns to the treating team promptly.
Price & Access Comparison Table (Practical Hospital/Community View)
Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy Status, Prescription Required
| Source | Typical Price Range | PBS Subsidy | Prescription Required |
|---|---|---|---|
| Hospital Supply | Usually supplied as inpatient stock | Often funded by hospital for inpatients | No community prescription needed for inpatient use |
| Chemist Warehouse / Priceline / TerryWhite Chemmart | Varies; ask for current quote | Depends on PBS listing and indication | Yes |
| Verified Online Pharmacies | Varies; consider shipping costs | Depends on PBS eligibility | Yes, e-prescription accepted |
Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability
- Confirm you have a valid prescription or e-prescription.
- Check PBS eligibility and possible subsidy for the indication.
- Compare community pharmacy stock and prices before discharge.
- Request oral solution if NG administration is required.
- Allow extra time for mail order to remote areas and arrange insulated packaging if needed.
- Contact the local pharmacist before discharge to arrange continuity of supply.
Registration & Regulation (TGA, ARTG, PBS)
TGA Approval
Is Nimotop officially approved in Australia?
Nimotop (nimodipine) is ARTG-registered in Australia and TGA documentation should be consulted for product information and prescribing details.
Hospital formularies rely on TGA/ARTG documentation when listing nimodipine for post-SAH use.
PBS Subsidy Details
How does PBS affect patient costs?
PBS subsidy depends on the indication, whether supply is hospital or community based, and current PBS schedule criteria.
If outpatient supply is not subsidised, patients may incur out-of-pocket costs and should discuss subsidised options or generics with the prescriber and pharmacist.
- Definitions:
- ARTG: Australian Register Of Therapeutic Goods — product registration
- TGA: Therapeutic Goods Administration — regulator
- PBS: Pharmaceutical Benefits Scheme — subsidy program
Storage & Handling (Patient And Pharmacy Guidance)
Household Storage In Australian Climate (Heat/Humidity)
How should patients store nimodipine at home in Australia?
Store below 25°C and protect from light to avoid degradation of active substance.
Avoid leaving capsules or oral solution in hot cars or in direct sunlight, especially during Australian summer heat.
Keep the bottle tightly closed and use the supplied dosing syringe for oral solution.
- Household storage checklist:
- Store below 25°C and away from direct sunlight
- Keep out of reach of children
- Use dosing syringe supplied with oral solution and discard after treatment completes
Cold-Chain Handling For Pharmacies
Does nimodipine need refrigeration?
Nimodipine is not a refrigerated product, but pharmacies should avoid temperature excursions during transport and storage.
For mail order to remote areas, include insulated packaging or temperature-moderating materials to avoid overheating in transit.
| Storage Temp | Handling Steps |
|---|---|
| Below 25°C | Store in a controlled pharmacy area away from heat sources |
| During Transport | Use insulated packaging in hot weather; advise recipient to store immediately on arrival |
Guidelines For Proper Use (Australian Pharmacist Counselling Style)
Australian Pharmacist Counselling Checklist
What should pharmacists cover when counselling about nimodipine?
- Confirm indication (post-aneurysmal SAH) and verify the 60 mg q4h x 21 days regimen.
- Emphasise that nimodipine is oral/NG only and must never be given IV.
- Review interactions, especially CYP3A4 inhibitors and alcohol.
- Advise on signs of hypotension and when to seek urgent care.
- Discuss driving and workplace safety and document counselling in dispensing records.
- Arrange follow-up with GP or specialist if side effects occur or supplies are interrupted.
Patient Advice From PBS And National Health Authorities
What written information should patients receive?
Provide the hospital discharge summary and written medication information that includes dosing, storage, interactions and emergency instructions.
Check PBS eligibility and help the patient with subsidy queries where applicable.
Keep a counselling note in the dispensing software and escalate clinical concerns to the treating specialist as required.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 9-14 days |
| Melbourne | Victoria | 9-14 days |
| Brisbane | Queensland | 9-14 days |
| Perth | Western Australia | 9-14 days |
| Adelaide | South Australia | 9-14 days |
| Hobart | Tasmania | 9-14 days |
| Darwin | Northern Territory | 9-14 days |
| Canberra | Australian Capital Territory | 9-14 days |
| Gold Coast | Queensland | 9-14 days |
| Newcastle | New South Wales | 9-14 days |
| Wollongong | New South Wales | 9-14 days |
| Geelong | Victoria | 9-14 days |
| Townsville | Queensland | 14-21 days |
| Cairns | Queensland | 14-21 days |